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ent comparison/substitute: the RA for the
vein graft. Dr Lytle’s comment in his
editorial, “in my judgment, the RA graft
is less predictable than the RITA graft in
regard to patency,” intrigued me. Over
the past 15 years as a practicing cardio-
thoracic surgeon, I have become pro-
foundly aware of the inadequacy of
veins, and since my recent attendance at
the enlightening and energy-invoking
symposium “Arterial Conduits for Myo-
cardial Revascularization” in Rome by
Dr G. F. Possatti and Dr A. M. Calafiore,
I believe the thrust should be to continue
to use double ITA grafts whenever pos-
sible (especially in the young) but to sub-
stitute the RA for the vein graft. Since
my return from this symposium, I have
tried to do this; perhaps I did not see (or
did not want to see) before, but many
patients have serious venous disease of
their legs precluding use of the saphe-
nous vein. I think one of the turning
points for me was when I recently (July
24, 2003) had to reoperate on an 83-year-
old woman, on whom I had placed 2
grafts at age 81. Her LITA had gone
down, I believe because I placed the graft
inadvertently above a stenosis and her
vein graft to a marginal artery occluded.
If her vein graft had stayed open, she
probably would not have needed reopera-
tion at age 83. I used a sequential RA
graft to the left anterior descending cor-
onary artery and the marginal branch on-
pump, and postoperatively she woke up
stating that this was easier than her first
operation. (Obviously this time both
grafts were working!)
A second reason to substitute the vein
for the RA graft could be the anticipated
longer-lasting results of the drug-eluting
stents used by interventional cardiolo-
gists. I know we are all interested in the
same end—stamping out coronary artery
disease effects— but it can be a little dis-
concerting for many surgeons currently
in practice to see their favored coronary
artery bypass grafts (LITA plus 2 veins)
going the way of the dodo bird. I want to
be so bold as to predict that the drug-
eluting stents will rival our saphenous
vein grafts (that is, by the time they fig-
ure out which drug, from which drug
family, how much eluting, over what pe-
riod of time, and so on, works; it might
take 20 years). Although we should never
be competitive with our interventional
colleagues because we have the same end
point in common, we must as surgeons
find something ancillary to their work. I
believe total arterial grafting (be it bilat-
eral ITA, LITA/RA, RITA, bilateral ITA/
gastroepiploic artery) may well be the
answer. As Dr Lytle most wisely stated at
the 2003 meeting of The American As-
sociation for Thoracic Surgery in Boston
(and I quote him often in this): “Did you
think you were going to be doing the
same operation for 100 years!?” Dr Lytle
continues to be a driving force leading all
our quests for the best coronary artery
bypass conduit.
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Angiotensin-converting enzyme
inhibitors predispose to hypotension
refractory to norepinephrine but
responsive to methylene blue
To the Editor:
We read with interest the brief communi-
cation of Grayling and Deakin1 describing
the methylene blue administration in a pa-
tient with refractory hypotension during
cardiac surgery. We’re currently using this
drug for patients with high cardiac output
and hypotension unresponsive to norepi-
nephrine at doses similar to those sug-
gested by Grayling and Deakin (up to 3
mg/kg in 2 different administration instead
of 2 mg/kg in a single dose). We would like
to suggest a possible predisposing factor of
vasoplegia that responds to methylene
blue: in our experience2 and in the litera-
ture3-5 it is evident that most episodes of
refractory hypotension are related to pre-
operative intake of angiotensin-converting
enzyme inhibitors (ACEI); even the patient
described in this report was assuming
ACEI (ramipril). After experiencing a dra-
matic refractory hypotension in a patient on
a program of ACEI,2 we started using
methylene blue in case of refractory hypo-
tension and withdrawing ACEI the day be-
fore surgery. We observed an immediate
and sustained response even at doses less
than 1 mg/kg.
We would like to reinforce this kind of
therapeutic approach and suggest a com-
mon predisposing factor that has been so
far underestimated: preoperative intake of
ACEI.
Donatella Sparicio, MD
Giovanni Landoni, MD
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Modified Fontan procedure in adults
To the Editor:
At the outset I must congratulate and thank
the authors of this article for this landmark
work on the Fontan procedure in an adult
population.1 This is going to be a bench-
mark for adult Fontan procedure in years to
come.
In the Western hemisphere the Fontan
surgery is done in children; adult patients
undergoing this procedure are exceptions,
not the rule. But in developing countries
adult patients for univentricular palliation,
with or without prior surgical palliation,
are quite common.2 As the authors have
addressed, the primary issue for these pa-
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